Day Zero Diagnostics Moves Headquarters to SmartLabs at Boston Landing
Company now occupies over 9,000 square feet of cutting-edge office and lab space
Boston—Aug. 03, 2020—Day Zero Diagnostics, Inc., an infectious disease diagnostics company using genome sequencing and machine learning to combat the rise of antibiotic- resistant infections, today announced the company is relocating its headquarters from the Pagliuca Harvard Life Lab to SmartLabs at Boston Landing.
The company will occupy over 9,000 square feet of office and lab space at 40 Guest Street in SmartLabs at Boston Landing – an 84,000-square-foot, cutting-edge innovation space in a state-of-the-art development encompassing approximately 15 acres of land along the Massachusetts Turnpike in Boston’s Brighton neighborhood. The new location is in the heart of a thriving contemporary area with easy access to public transportation, shops, restaurants, sports facilities, and green spaces.
The new facility will support the continued development of Day Zero’s diagnostic system that is intended to help physicians quickly and accurately diagnose and treat life-threatening infections. The system promises to help patients with severe infections receive the most effective antibiotic treatment on the first day they are admitted to the hospital—day zero.
“Despite the challenges the whole world has faced this year, we feel lucky to celebrate our progress as a company and this significant milestone as we begin an exciting new chapter in our story,” said Jong Lee, CEO of Day Zero Diagnostics. “Day Zero is committed to modernizing the way we address the growing global threat of antibiotic resistance. We look forward to advancing our efforts in our new, state-of-the-art facility in one of the largest life science communities in the world.”
About Day Zero Diagnostics
Day Zero Diagnostics, Inc., based in Boston, is pioneering a new class of infectious disease diagnostics using whole-genome sequencing and machine learning to revolutionize how the world fights the growing threat of antibiotic resistance. The company’s mission is to change the way infectious diseases are diagnosed and treated by rapidly identifying both the species and the antibiotic resistance profile of severe infections without the need for a culture. By using sequencing, Day Zero also enables big data approaches for managing healthcare-associated infection outbreaks. Day Zero Diagnostics was founded in 2016 by a team of clinicians and scientists from Harvard University and Massachusetts General Hospital. The company has been recognized as a leading innovator by Carb-X, MedTech Innovator, TedMed Hive, Xconomy, HealthTech Arkansas, and MassChallenge HealthTech. For more information visit www.dayzerodiagnostics.com or follow us on Twitter at @dayzerodx.